AMG National Trust Bank Sells 103,958 Shares of Bristol Myers Squibb Company $BMY

AMG National Trust Bank decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 86.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 15,739 shares of the biopharmaceutical company’s stock after selling 103,958 shares during the quarter. AMG National Trust Bank’s holdings in Bristol Myers Squibb were worth $710,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. Lion Street Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 13.9% in the third quarter. Lion Street Advisors LLC now owns 14,091 shares of the biopharmaceutical company’s stock worth $636,000 after buying an additional 1,722 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Bristol Myers Squibb in the 3rd quarter worth approximately $451,000. Berkeley Capital Partners LLC grew its stake in shares of Bristol Myers Squibb by 8.8% during the 3rd quarter. Berkeley Capital Partners LLC now owns 53,366 shares of the biopharmaceutical company’s stock worth $2,407,000 after purchasing an additional 4,294 shares during the period. Y.D. More Investments Ltd purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at approximately $146,000. Finally, ICICI Prudential Asset Management Co Ltd lifted its stake in shares of Bristol Myers Squibb by 85.8% in the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 181,849 shares of the biopharmaceutical company’s stock valued at $8,201,000 after purchasing an additional 84,000 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $60.66 on Monday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a 50 day moving average price of $56.22 and a 200 day moving average price of $50.03. The stock has a market capitalization of $123.53 billion, a P/E ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the company earned $1.67 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were paid a $0.63 dividend. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Analysts Set New Price Targets

A number of research analysts have weighed in on BMY shares. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up previously from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup upped their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Finally, Leerink Partners lifted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $60.19.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.